Foresee Pharmaceuticals is seeing its dual-engine growth strategy reach a "harvest period" with its lead product, CAMCEVI, and the successful readout of its pediatric pipeline.

• Commercial Growth: January revenue reached NT$12.79 million (+14.82% YoY), consisting entirely of royalty shares from CAMCEVI (6-month depot) sales in the U.S. Following its 2022 U.S. launch, the product expanded into Europe in 2025. The 3-month depot formulation has also received FDA approval, with a U.S. launch expected by late 2026.
• Clinical Milestone: The Phase III trial for FP-001 in Central Precocious Puberty (CPP) reached its primary endpoint (p=0.0005). The Independent Data Safety Monitoring Board (DSMB) provided its fourth positive recommendation to continue the trial for long-term safety monitoring. An NDA submission to the U.S. FDA is planned for Q3 2026.
• Pipeline Diversification: The company is advancing its SIF-LAI (Stable Injectable Formulation) technology. Other assets include Aderamastat (FP-025) for allergic asthma, Linvemastat (FP-020) (licensed to Primevera Therapeutics), and Mirivadelgat (FP-045) for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), which entered Phase II last year.

Resource: 逸達雙引擎推進 CAMCEVI全球放量、FP-001三期報捷